




ACTAS Dermo-Sifiliográficas

Full English text available at
www.actasdermo.org



ORIGINAL ARTICLE

Acral Melanoma in the Caucasian Population: A Comprehensive Cohort Study on Epidemiological, Clinicopathological, and Prognostic Features



J. Angel-Baldo^{a,b,*,1}, S. Podlipnik^{c,1}, A. Azón^a, A. Boada^d, A. Arrieta^d, J. Marcoval^e, C. López-Sánchez^f, M. Sàbat^g, S. Segura^h, D. Bodetⁱ, N. Curcó^j, D. Lopez-Castillo^k, J. Solà^l, M. Quintana-Codina^m, C. Baliu-Piquéⁿ, M. Just-Sarobé^o, S. Martín-Sala^p, J. Malveyh^{c,q}, S. Puig^{c,q}, C. Carrera^{c,q,*,2}, R.M. Martí^{b,r,2}, Network of Melanoma Centers of Catalonia⁺

^a Department of Dermatology, Hospital Universitari Sant Joan de Reus, Universitat Rovira i Virgili, Reus, Catalonia, Spain

^b Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Catalonia, Spain

^c Department of Dermatology, Hospital Clínic Barcelona, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain

^d Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain

^e Department of Dermatology, Hospital Universitari de Bellvitge, Barcelona, Catalonia, Spain

^f Department of Dermatology, Hospital de la Santa Creu i Sant Pau, IIB SANT PAU, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain

^g Department of Dermatology, Hospital Universitari Parc Taulí, Sabadell, Catalonia, Spain

^h Department of Dermatology, Hospital del Mar, Hospital del Mar Research Institute-IMIM, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain

ⁱ Department of Dermatology, Hospital Universitari Vall d'Hebrón, Barcelona, Catalonia, Spain

^j Department of Dermatology, Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain

^k Department of Dermatology, Hospital Moises Broggi, Sant Joan Despí, Catalonia, Spain

^l Department of Dermatology, Hospital General de Granollers, Granollers, Catalonia, Spain

^m Department of Dermatology, Hospital Universitari Sagrat Cor, Grupo Quironsalud, Barcelona, Catalonia, Spain

ⁿ Department of Dermatology, Hospital Universitari d'Igualada, Igualada, Catalonia, Spain

^o Department of Dermatology, Hospital Universitari Joan XXIII, Tarragona, Catalonia, Spain

^p Department of Dermatology, Hospital Dos de Maig, Barcelona, Catalonia, Spain

^q Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) Instituto de Salud Carlos III, Spain

^r Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

Received 10 August 2024; accepted 9 October 2024

Available online 10 January 2025

* Corresponding author.

E-mail addresses: joan.an.ba@gmail.com (J. Angel-Baldo), ccarrera@clinic.cat (C. Carrera).

⁺ The members of the Melanoma Centers Network of Catalonia are presented in [Appendix 1](#).

¹ These authors contributed equally and should be considered the lead authors.

² Senior authors.

<https://doi.org/10.1016/j.ad.2024.10.060>

0001-7310/© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

KEYWORDS

Acral melanoma;
Risk factor;
Prognostic factor;
Cutaneous
melanoma;
Survival analysis;
Foot melanoma;
Hand melanoma

PALABRAS CLAVE

Melanoma acral;
Factor de riesgo;
Factor pronóstico;
Melanoma cutáneo;
Análisis de
supervivencia;
Melanoma de pie;
Melanoma de mano

Abstract

Background: Acral melanoma is associated with poor prognosis. Studying the characteristics and prognosis of Caucasian patients is crucial to understand the distinct features of this tumor. **Objectives:** To analyze the epidemiological, clinicopathological, and prognostic features of acral melanoma in Caucasian patients.

Methods: We conducted a retrospective, multicenter, cohort study of acral melanoma from a database across 20 hospitals from South Europe from January 2000 to December 2019.

Results: A total of 733 acral melanomas were identified (median age, 67.5 years; 95.2%, Caucasians; 77.5% of which were located on the feet). Overall, 77.5% of cases were invasive melanomas. Foot melanomas had a higher proportion of invasive cases (80.8% vs 69.8%; $p=0.003$), stages III and IV at diagnosis (24.8% vs 11.7%; $p<0.001$), thicker Breslow depth (2.8 mm vs 2.0 mm; $p=0.021$) and a higher rate of positive sentinel lymph node biopsy (SLNB) (30.7% vs 15.7%; $p=0.012$). Thicker Breslow depth and later age of onset were risk factors for melanoma-specific survival. Thicker Breslow depth and ulceration were independent prognostic factors of relapse-free survival. Melanoma location and histopathological subtype were not associated with worse prognosis. Recurrences were a common finding (27.7%), with distant metastases appearing earlier than locoregional recurrences (1.32 years [IQR, 1.12–1.87] vs 2.14 years [IQR, 1.68–2.70]; $p=0.015$).

Conclusion: This study, the largest in a predominantly Caucasian population, underscores the unfavorable outcomes of acral melanoma. Foot melanomas exhibited delayed detection, increased invasiveness, thicker Breslow depth, increased SLNB involvement, and higher AJCC stages. The high recurrence rate and early distant metastases emphasize the critical role of intensive follow-up and routine imaging modalities to detect asymptomatic relapses.

© 2025 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Melanoma acral en población caucásica: estudio de cohorte sobre factores epidemiológicos, clinicopatológicos y pronósticos

Resumen

Introducción: El melanoma acral está asociado con un pronóstico desfavorable. El estudio sobre las características y el pronóstico en los pacientes caucásicos puede ser crucial para comprender las características distintivas de este tumor.

Objetivos: Analizar las características epidemiológicas, clinicopatológicas y pronósticas del melanoma acral en los pacientes caucásicos.

Material y métodos: Estudio de cohorte retrospectivo de melanoma acral a partir de una base de datos multi-institucional en 20 hospitales españoles, entre enero de 2000 y diciembre de 2019.

Resultados: Se identificaron un total de 733 melanomas acrales (edad media: 67,5 años, el 95,2% caucásicos y el 77,5% en los pies). En general, el 77,5% de los casos fueron invasivos. Los melanomas localizados en los pies tuvieron una mayor proporción de casos invasivos (80,8 vs. 69,8%; $p=0,003$), estadios III y IV al diagnóstico (24,8 vs. 11,7%; $p<0,001$), valores de Breslow más altos (2,8 vs. 2,0 mm; $p=0,021$) y una mayor tasa de positividad de biopsia selectiva del ganglio centinela (BSGC) (30,7 vs. 15,7%; $p=0,012$). Un mayor grosor de Breslow y una edad de aparición más tardía fueron factores de riesgo para menor supervivencia específica por melanoma. Un mayor grosor de Breslow y la ulceración fueron los factores pronósticos independientes menor supervivencia libre de recaída. La localización del melanoma y el subtipo histopatológico no se asociaron con un peor pronóstico. Las recurrencias fueron frecuentes (27,7%), con a distancia apareciendo antes que las recurrencias locorregionales (1,32 años [IQR: 1,12-1,87] vs. 2,14 años [IQR: 1,68-2,70]; $p=0,015$).

Conclusión: Este estudio, el mayor en una población predominantemente caucásica, subraya los resultados desfavorables del melanoma acral. Los melanomas en los pies mostraron una detección tardía, mayor proporción de melanomas invasivos, valores de Breslow más profundos, mayor positividad o afectación de BSGC y estadios AJCC más altos. La alta tasa de recurrencia y las metástasis a distancia tempranas enfatizan el papel crítico del seguimiento intensivo y las pruebas de imagen rutinarias para detectar recaídas asintomáticas.

© 2025 AEDV. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licencias/by-nc-nd/4.0/>).

Introduction

Acral melanoma affects all populations worldwide and is recognized as a distinct melanoma subgroup due to its unique characteristics including epidemiological, clinicopathological, molecular and prognostic features.^{1–8}

According to the World Health Organization (WHO), acral melanoma are those occurring on the glabrous (non-hair-bearing) skin of the volar aspects of the fingers and toes, palms, soles, and nail beds.⁸ In addition, acral lentiginous melanoma (ALM) is a histopathological subtype of melanoma, characterized by specific morphological features as well.^{8–10}

Acral melanoma is clearly associated with poorer prognosis vs cutaneous melanoma found in other locations.^{1,2,6,8,10,11} This adverse prognosis has been attributed to several factors, such as thicker Breslow depth and more advanced stages, which could be attributed to delayed diagnosis in part due to older age and non-visible anatomic locations, but also to a more aggressive behavior of the histopathological subtype or molecular background on non-sun exposed areas.^{1,2,4,6,8,10–12}

In the present study, we used a large series of acral melanoma cases from a Southern European multicentre melanoma network over two decades to assess the epidemiological, clinicopathological and prognostic characteristics focusing on melanoma location, and analyze the recurrence patterns, melanoma-specific survival (MSS) and relapse-free survival (RFS) which can influence the follow-up and management of patients with acral melanoma.

Materials and methods

The Network of Melanoma Centers of Catalonia database (*Xarxa Melanoma Catalunya*),^{13–15} a collaborative, prospective, multicenter database project including more than 20 hospitals from Northeast Spain was used to perform a retrospective study of patients with acral melanoma from January 2000 to December 2019 and followed up until August 2023.

All patients diagnosed with melanoma on acral sites with confirmed and properly registered melanoma diagnosed at these centers were initially considered to be included in the study. Data collection and analysis of all patients were approved under the protocol reference No. (HCB IRB; approval #2015/0298). Cases that were not consistent with the WHO definition of acral melanoma were excluded, keeping only those localized on the glabrous skin of hands and feet, including the nail apparatus. Cases were also excluded when location was not concordant, or when poorly defined.

The main variable used to analyze data was the anatomical location between hand and foot. Information on demographics, melanoma attributes, and prognostic data were recorded. Variables analyzed included gender, age at diagnosis, race and number of primary melanomas. Melanoma features included location (foot vs hand); stage (in situ vs invasive), staging according to the American Joint Committee on Cancer (AJCC) 8th edition, histopathological subtype (ALM, superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), nodular melanoma [NM] and other subtypes), Breslow depth, presence of mitotic figures, ulceration, associated nevi and satellitosis, sentinel

lymph node biopsy (SLNB) performance and status. Prognostic data included recurrence patterns: timing and location (locoregional [lymph node or in-transit/satellitosis] and distant organs). Survival analysis was performed using 5-year and across the years MSS and RFS using the Kaplan–Meier method. Melanoma-related deaths were determined based on the patients' death certificates and clinical history. MSS alludes to the time from melanoma excision to the date of death directly attributed to the disease. RFS alludes to the period from melanoma excision to disease detection in patients who had no residual disease after surgical procedures.

Statistical analysis

The frequencies and percentages were used to portray the distributions of categorical variables, while the distributions of continuous variables were expressed as median and interquartile range (IQR). The analysis of categorical variables included the Chi-squared test, or Fisher's exact test when any expected cell count was <5. Meanwhile, ordinal variables were expressed using the trend test. In the context of comparing independent continuous variables, the Wilcoxon rank sum test was employed.

The cohort median follow-up was estimated using the reverse Kaplan–Meier estimator. This estimate was conducted by applying the *prodlim* package (version 2023.3.31) in R, using both *prodlim* and *Hist* functions.

We conducted univariate and multivariate survival analyses, presenting HRs with 95% confidence intervals from fitted Cox proportional hazard models. These models were created using the *coxph* function in the survival software package (version 3.5.5) in R. Hazard ratios (HRs) were estimated for acral melanoma location (feet vs hands), independently adjusted for age at diagnosis, gender, Breslow Index, ulceration, and histological subtype. A concise Cox regression table showed both univariate and multivariate hazard ratios for improved data visualization.

Within the metastatic patient subgroup, we evaluated the relapse timing of acral melanomas using a cumulative event plot, calculating the median survival time. Additionally, we used Sankey plots as a powerful visual tool to depict the first metastatic locations of acral melanoma patients. Furthermore, we performed computations to ascertain the proportions of patients in each group with disease progression.

All statistical analyses were performed using the computing environment R version 4.3.1 (2023-06-16) and RStudio (version 2023.6.1.524). *p* values < 0.05 were considered statistically significant.

Results

A total of 906 patients were identified out of 19,951 registered in the regional database (Network of Melanoma Centers of Catalonia). After per-protocol exclusions (melanomas located on non-glabrous skin of hands and feet, or locations not concordant-poorly defined), the number of total acral melanomas of this study were 733 from a total of 730 patients. The median follow-up time of the cohort calcu-

Table 1 Demographic and histopathological features of all melanomas.

Variable	Overall, N = 733	Location		p-Value ^a
		Foot, N = 568	Hand, N = 165	
Gender, n (%)				0.645
Female	429 (58.5%)	335 (59.0%)	94 (57.0%)	
Male	304 (41.5%)	233 (41.0%)	71 (43.0%)	
Age, median (IQR)	67.5 (53.7–78.6)	67.8 (53.9–79.4)	65.7 (53.2–76.2)	0.099
Race, n (%)				0.371
White	338 (95.2%)	266 (96.0%)	72 (92.3%)	
Latin	8 (2.3%)	5 (1.8%)	3 (3.8%)	
Asian	4 (1.1%)	2 (0.7%)	2 (2.6%)	
Indian	2 (0.6%)	1 (0.4%)	1 (1.3%)	
Gipsy	1 (0.3%)	1 (0.4%)	0 (0.0%)	
Black	1 (0.3%)	1 (0.4%)	0 (0.0%)	
Missing	379	292	87	
Staging, n (%)				0.003
In situ	157 (21.7%)	108 (19.2%)	49 (30.2%)	
Invasive	568 (78.3%)	455 (80.8%)	113 (69.8%)	
Missing	8	5	3	
AJCC 2017, n (%)				<0.001
0	156 (21.5%)	107 (19.0%)	49 (30.2%)	
I	186 (25.7%)	139 (24.7%)	47 (29.0%)	
II	224 (30.9%)	177 (31.4%)	47 (29.0%)	
III	145 (20.0%)	128 (22.7%)	17 (10.5%)	
IV	14 (1.9%)	12 (2.1%)	2 (1.2%)	
Missing	8	5	3	
Number of primary melanomas, n (%)				0.189
Multiple primary melanomas	42 (5.7%)	36 (6.3%)	6 (3.6%)	
Single primary melanoma	691 (94.3%)	532 (93.7%)	159 (96.4%)	
Associated nevus, n (%)				<0.001
De novo melanoma	363 (87.7%)	265 (84.1%)	98 (99.0%)	
Nevus-associated melanoma	51 (12.3%)	50 (15.9%)	1 (1.0%)	
Missing	319	253	66	
Histological subtype, n (%)				0.030
Acral lentiginous	666 (90.9%)	509 (89.6%)	157 (95.2%)	
Nodular	67 (9.1%)	59 (10.4%)	8 (4.8%)	

Data expressed as No. (%) unless otherwise indicated.

IQR, Interquartil range; AJCC, American Joint Committee on Cancer;

^a Pearson's chi-squared test; Wilcoxon rank sum test; Fisher's exact test.

lated with the reverse Kaplan–Meier methods was 8.34 years with an IQR, of 4.89–13.01 years.

Demographic and histopathological features

The demographic and histopathological features of all melanomas are shown in Table 1. The features of invasive melanomas (N = 568, 77.5%) are shown in Table 2. Overall, median age was 67.5 years (IQR, 53.7–78.6; 58.5%, women). The anatomic distribution of the tumors was 568 on the feet (77.5%) and 165 on the hands (22.5%). A total of 95% of the patients were Caucasian.

Considering the whole series, all cases were histopathologically categorized as ALM (N = 666, 90.9%) and NM (N = 67, 9.1%), with the foot melanoma group having more NM (10.4% vs 4.8%; $p = 0.030$). The hand melanoma group had more in situ and stage I cases (59.2% vs 43.7% on feet; $p < 0.001$), while the foot melanoma group had more advanced cases at diagnosis (stages III and IV) (24.8% vs 11.7%; $p < 0.001$). Significant differences were observed regarding the number of invasive cases when foot and hand tumors were compared (80.8% vs 69.8%, respectively; $p = 0.003$). Overall, 42 patients (5.7%) exhibited multiple primary melanomas, while only 3 patients of this cohort developed > 1 acral

Table 2 Demographic and histopathological features of invasive melanomas.

Variable	Overall, N = 568	Location		p-Value ^a
		Foot, N = 455	Hand, N = 113	
<i>Gender, n (%)</i>				0.573
Female	315 (55.5%)	255 (56.0%)	60 (53.1%)	
Male	253 (44.5%)	200 (44.0%)	53 (46.9%)	
<i>Age, median (IQR)</i>	69.5 (56.4–79.4)	70.5 (56.4–79.9)	68.8 (56.6–77.7)	0.375
<i>AJCC 2017, n (%)</i>				0.014
I	185 (32.6%)	138 (30.3%)	47 (41.6%)	
II	224 (39.4%)	177 (38.9%)	47 (41.6%)	
III	145 (25.5%)	128 (28.1%)	17 (15.0%)	
IV	14 (2.5%)	12 (2.6%)	2 (1.8%)	
<i>Number of primaries melanomas, n (%)</i>				0.854
Multiple primary melanomas	27 (4.8%)	22 (4.8%)	5 (4.4%)	
Single primary melanoma	541 (95.2%)	433 (95.2%)	108 (95.6%)	
<i>Breslow, median (IQR)</i>	2.7 (1.3–5.0)	2.8 (1.3–5.0)	2.0 (1.0–4.2)	0.021
Missing	5	4	1	
<i>Ulceration, n (%)</i>				0.109
Absent	290 (52.3%)	225 (50.6%)	65 (59.1%)	
Present	265 (47.7%)	220 (49.4%)	45 (40.9%)	
Missing	13	10	3	
<i>Mitotic index mm², n (%)</i>				0.743
≥1 mitosis	316 (73.5%)	254 (73.8%)	62 (72.1%)	
0 mitosis	114 (26.5%)	90 (26.2%)	24 (27.9%)	
Missing	138	111	27	
<i>Histological subtype, n (%)</i>				0.092
Acrall lentiginous	502 (88.4%)	397 (87.3%)	105 (92.9%)	
Nodular	66 (11.6%)	58 (12.7%)	8 (7.1%)	
<i>Satellitosis, n (%)</i>				0.096
Absent	541 (95.2%)	430 (94.5%)	111 (98.2%)	
Present	27 (4.8%)	25 (5.5%)	2 (1.8%)	
<i>Associated nevus, n (%)</i>				0.011
De novo melanoma	307 (91.4%)	233 (89.3%)	74 (98.7%)	
Nevus-associated melanoma	29 (8.6%)	28 (10.7%)	1 (1.3%)	
Missing	232	194	38	
<i>Sentinel lymph node biopsy, n (%)</i>				0.256
Direct lymphadenectomy	17 (3.2%)	16 (3.8%)	1 (0.9%)	
Not indicated	102 (19.2%)	76 (17.9%)	26 (24.3%)	
SLNB not performed	94 (17.7%)	77 (18.1%)	17 (15.9%)	
SLNB performed	319 (60.0%)	256 (60.2%)	63 (58.9%)	
Missing	36	30	6	
<i>Sentinel lymph node biopsy status, n (%)</i>				0.012
Affected	93 (27.6%)	82 (30.7%)	11 (15.7%)	
Not affected	244 (72.4%)	185 (69.3%)	59 (84.3%)	
Missing	231	188	43	

Data are expressed as No. (%) unless otherwise indicated; IQR, interquartil range; AJCC, American Joint Committee on Cancer.

^a Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test.




Figure 1 Kaplan–Meier curves for melanoma-specific survival (A) and relapse-free survival (B).

melanoma. Moreover, foot melanomas had a higher percentage of nevus-associated melanoma vs the hand melanoma group (15.9% vs 1.0%; $p < 0.001$).

Histopathological features of invasive melanomas

Regarding invasive melanomas, the hand melanoma group had a higher percentage of stage I and II melanomas (83.2%

vs 69.2%; $p = 0.014$). Median Breslow of the series was 2.7 mm (IQR, 1.3–5.0) with the foot melanoma group having thicker Breslow depth [2.8 mm (IQR, 1.3–5.0) vs 2.0 mm (IQR, 1.0–4.2); $p = 0.021$]. Ulceration was present in 47.7% of all cases; no significant differences were detected between hand and foot acral melanoma. The distribution of the histological subtypes was 88.4% for ALM and 11.6% for NM, with no differences being reported between hand and foot

acral melanoma. Foot melanomas had a higher percentage of nevus-associated melanoma vs the hand melanoma group (10.7% vs 1.3%; $p=0.011$). Regarding stage III patients, we observed that 93 patients (64.1%) were diagnosed via SLNB and 52 cases (35.9%) via visible locoregional disease at the time of diagnosis. SLNB was performed in 319 cases (60%) with affected status in 93 cases (27.6%). A statistically significant difference in SLNB status was observed with a higher number of positive SLNB in the foot melanoma group (30.7% vs 15.7%; $p=0.012$).

Survival analysis

Overall, the 5-year MSS rate was 71.5% (95%CI, 67.4–75.8). These survival rates were 69.1% (95%CI, 64.6–74.0) for the foot group and 81.2% (95%CI, 73.1–90.2) for the hand melanoma group. Overall, the 5-year RFS rate was 61.8% (95%CI, 57.5–66.5); 59.5% (95%CI, 54.6–64.8) for the foot group and 70.9% (95%CI, 61.4–81.6) for the hand melanoma group. The Kaplan–Meier curves showed that foot melanomas had statistically significant lower MSS ($p=0.019$) and RFS rates ($p=0.011$) vs hand melanomas. In this series, no patients with in situ melanoma died of melanoma-related deaths. The results are shown in Fig. 1.

Univariate Cox regression analysis of MSS showed that foot location of melanoma, later age of onset, male gender, thicker Breslow depth, presence of ulceration and nodular melanoma subtype were associated with worse prognosis.

The multivariate Cox regression analysis confirmed that later age of onset (>75 years; HR, 1.61; 95%CI, 1.05–2.46; $p=0.030$), and thicker Breslow depth (>1.0 – 2 mm; HR, 5.85; 95%CI, 1.76–19.45; $p=0.004$; >2.0 – 4 mm; HR, 11.18; 95%CI, 3.41–36.70; $p<0.001$; >4 mm; HR, 14.20; 95%CI, 4.28–47.06; $p<0.001$) were independent predictors of worse MSS.

Regarding RFS, the overall 5-year RFS rate was 61.8% (95%CI, 57.5–66.5) with 5-year RFS rates of 59.5% (95%CI, 54.6–64.8) for the foot group and 70.9% (95%CI, 61.6–81.6) for the hand melanoma group. Univariate Cox regression analysis showed that foot location of melanoma, thicker Breslow depth, presence of ulceration and nodular melanoma subtype were associated with worse RFS. Nevertheless, multivariate regression models found that only Breslow depth (>1.0 – 2 mm; HR, 3.91; 95%CI, 1.62–9.45; $p=0.002$; >2.0 – 4 mm; HR, 7.68; 95%CI, 3.23–18.29; $p<0.001$; >4 mm; HR, 10.12; 95%CI, 4.19–24.41; $p<0.001$) and the presence of ulceration (HR, 1.57, 95%CI 1.11–2.22; $p=0.011$) were independent risk factors of RFS.

Data associated with univariate and multivariate Cox regression models for MSS and RFS are shown in Table 3.

For the recurrence pattern, the median time to the index metastasis was 1.74 years (IQR, 1.48–2.17) (Fig. 2). Most patients (81.7%) who recurred developed the first metastasis within the first 4 years of follow-up.

A total of 202 patients (27.7%) developed recurrences after a mean follow-up of 100 months. The most common site of relapse was locoregional ($n=121$; 59.9%), while 81 patients (40.1%) developed distant metastases. For the location of the index metastasis, Kaplan–Meier curves showed that distant metastases appeared earlier than locoregional

metastases did (median time, 1.32 years (IQR, 1.12–1.87) vs 2.14 years (IQR, 1.68–2.70); $p=0.015$) (Fig. 2). Most distant metastases were pulmonary (34.6%), followed by hepatic (13.6%), associated with the central nervous system (12.3%), and distant lymphatic (12.3%) metastases. The distribution of the index metastases is illustrated in Fig. 3.

Discussion

As far as we know, the present 20-year retrospective study of acral melanoma in Europe is the largest series conducted in a predominantly white population.

Melanoma on the acral regions affects all populations worldwide. However, represents a significant number of cases (20% up to 70%) in countries with a lower incidence of sun-related melanoma, such as those in Asian, African, and Latin American regions.^{8,16–19} Given its importance, most studies on acral melanoma focus on non-Caucasian populations.

Acral melanoma is a rare entity with distinctive peculiarities associated with poorer prognosis vs cutaneous melanoma found in different locations.^{2,6,10,11,20,21} This adverse prognosis has been attributed to several factors, as mentioned. In our cohort, a significant number of cases were diagnosed with thicker Breslow depth, high prevalence of ulceration and advanced stages, as most studies reported.^{2,6,10–12,21,22} Notably, 21.9% of our cohort was diagnosed with non-localized AJCC 8th edition stage disease (stage III and IV), which is consistent with other series.^{6,21,23} This percentage of non-localized stages is considerably higher than that of the series of non-acral melanomas.¹¹ Moreover, acral melanoma is associated with older age and most cases occurred on the feet, as we have already seen.^{2,6,10–12,20,22,24} These findings collectively suggest a notable delay in diagnosis, predominantly attributed to the less conspicuous location of melanomas, such as the feet, a factor that is particularly pertinent in older populations, as proposed by other authors.^{2,4,10–15} Overall, about 20% up to 30% of melanomas are originated from a melanocytic nevus precursor.^{25–27} Nevus-associated melanomas have been associated with a younger age at diagnosis, higher nevus counts, thinner melanomas, and intermittently sun-exposed body locations such as the trunk. Histopathologically, they develop SSM and harbor *BRAF* mutations.^{25–27} It is remarkable that in our population the prevalence of nevus-associated melanomas was only 1% on the hand melanoma group and 16% on the foot melanoma group, which could be explained by the relatively older population of the cohort, the absence of SSM and the low incidence of *BRAF* mutations that acral melanomas tend to associate. Moreover, a few studies on ALM have indicated that melanomas tend to occur in areas of the hands and feet prone to mechanical stress.^{22,28–31} Pressure, trauma and physical stress on the feet could play a role in the pathogenesis of nevus-associated melanomas and explain the differences between hand and foot melanoma group.

Histological subtype and melanoma location have been a matter of discussion regarding their impact on prognosis. Some studies suggest that ALM or acral melanoma location are associated with a poorer prognosis^{2,6,10,11,20,21} while other indicate that their prognosis is similar to that of other

Table 3 Univariate and multivariate Cox regression analysis of melanoma-specific survival (MSS) and relapse-free survival (RFS).

	MSS		RFS	
	HR (univariable)	HR (multivariable)	HR (univariable)	HR (multivariable)
<i>Location</i>				
Foot	•	•	•	•
Hand	0.59 (0.37–0.92, <i>p</i> = 0.020)	0.70 (0.44–1.12, <i>p</i> = 0.139)	0.59 (0.39–0.89, <i>p</i> = 0.012)	0.72 (0.47–1.09, <i>p</i> = 0.119)
<i>Age (tertiles)</i>				
<58.3	•	•	•	•
58.3–75	1.64 (1.08–2.48, <i>p</i> = 0.019)	1.43 (0.94–2.18, <i>p</i> = 0.099)	1.29 (0.90–1.86, <i>p</i> = 0.166)	1.03 (0.71–1.49, <i>p</i> = 0.882)
>75	2.02 (1.33–3.06, <i>p</i> = 0.001)	1.61 (1.05–2.46, <i>p</i> = 0.030)	1.40 (0.96–2.02, <i>p</i> = 0.077)	1.17 (0.81–1.70, <i>p</i> = 0.410)
<i>Gender</i>				
Female	•	•	•	•
Male	1.58 (1.17–2.15, <i>p</i> = 0.003)	1.28 (0.94–1.76, <i>p</i> = 0.122)	1.29 (0.97–1.72, <i>p</i> = 0.075)	1.03 (0.77–1.39, <i>p</i> = 0.819)
<i>Breslow depth</i>				
≤1.0 mm	•	•	•	•
>1.0–2 mm	5.31 (1.85–15.21, <i>p</i> = 0.002)	5.85 (1.76–19.45, <i>p</i> = 0.004)	3.41 (1.57–7.41, <i>p</i> = 0.002)	3.91 (1.62–9.45, <i>p</i> = 0.002)
>2.0–4 mm	11.95 (4.32–33.10, <i>p</i> < 0.001)	11.18 (3.41–36.70, <i>p</i> < 0.001)	7.81 (3.74–16.31, <i>p</i> < 0.001)	7.68 (3.23–18.29, <i>p</i> < 0.001)
>4 mm	17.77 (6.51–48.50, <i>p</i> < 0.001)	14.20 (4.28–47.06, <i>p</i> < 0.001)	11.44 (5.54–23.61, <i>p</i> < 0.001)	10.12 (4.19–24.41, <i>p</i> < 0.001)
<i>Ulceration</i>				
Absent	•	•	•	•
Present	2.94 (2.11–4.10, <i>p</i> < 0.001)	1.37 (0.94–1.99, <i>p</i> = 0.100)	3.14 (2.31–4.27, <i>p</i> < 0.001)	1.57 (1.11–2.22, <i>p</i> = 0.011)
<i>Histological subtype</i>				
Acral lentiginous	•	•	•	•
Nodular	2.08 (1.42–3.07, <i>p</i> < 0.001)	1.22 (0.81–1.84, <i>p</i> = 0.348)	1.52 (1.02–2.27, <i>p</i> = 0.040)	0.86 (0.57–1.31, <i>p</i> = 0.490)

HR, hazard ratio

melanoma subtypes and locations.^{4,12,22–24,32,33} In our series, when comparing hands vs feet melanomas, we observed that melanomas on the feet exhibited thicker Breslow depths, more prevalent SLNB involvement, and higher AJCC 8th edition stages. However, the location of melanoma and its histopathological subtype were not associated with poorer prognosis in terms of MSS or RFS. Thicker Breslow depth and later age of onset (>75 years) were the only independent prognostic factors for MSS, while thicker Breslow depth and ulceration were independent risk factors for RFS.

Former studies suggest that there could be differences in the dynamics of metastatic spread between acral and non-acral melanoma, particularly in terms of higher rates of both recurrence and distant metastases in acral melanoma.^{2,6,10,12,34–43} Moreover, it has been reported that risk factors for lymphatic or hematogenous metastases may vary,^{44,45} where thicker Breslow depths have been reported as a predictor for hematogenous metastases.⁴⁵ Furthermore, patients with earlier stages developed relapses later than those with more advanced stages, which was clearly marked in distant metastasis.^{42,46,47} In our research, we observed

a high rate of melanoma relapses with predominance of locoregional metastases; however, a significant proportion of cases also developed distant metastases. Notably, distant metastases showed earlier than locoregional metastases and did so in a shorter period of time vs other series published to this date,^{42,48–50} which could be explained by the thick Breslow depths reported in the study leading to a major risk for distant and earlier metastasis. As far as we know, there are no other specific studies on this phenomenon in acral melanoma series. These observations underscore the complexity and variability of the metastatic behaviour of melanomas and highlight the importance of considering routine imaging modalities to detect asymptomatic recurrences or metastases 3–5 years after diagnosis, depending on the risk of relapse, according to the National Comprehensive Cancer Network (NCCN) guidelines.⁵¹

This study has the limitations inherent to its retrospective design. However, data were prospective and multicentrically collected. There are missing values in significant data points, such as the exact location on acral zones, the socioeconomic factors, the genetic testing of the tumors, and the




Figure 2 Recurrence patterns. Kaplan–Meier curves time to index metastasis (A) and type of index metastasis (B).

margins obtained in melanoma-related surgical procedures. In the case of recurrences, we did not explore whether these patients developed synchronous metastases or subsequent distant metastases in patients initially presenting with locoregional metastases. Due to the heterogeneity of surgical procedures and systemic therapies throughout 2

decades, we did not delve into the outcomes based on the therapies received.

In conclusion, we present the largest study conducted on acral melanomas in a predominantly Caucasian population. A significant number of cases were diagnosed with thick Breslow depth, high prevalence of ulceration,




Figure 3 Sankey plot showing the distribution of index metastases.

advanced stages and low prevalence of nevus-associated melanomas. Melanomas originating on the feet were later detected—were more associated with nevus—had a higher proportion of nodular subtype, and more advanced AJCC 8th edition stages vs those arising on the hand. Thicker Breslow depth and later age of onset were independent prognostic factors for MSS, while thicker Breslow depth and ulceration were independent risk factors for RFS. Melanoma location and histopathological subtype were not associated with a poorer prognosis. Recurrences were a common finding, with distant metastases appearing earlier than locoregional recurrences, which highlights the importance of intensive follow-up and routine imaging modalities to monitor asymptomatic recurrences.

Funding

Melanoma research at Hospital Universitari Arnau de Vilanova of Lleida was supported by grants from ISCIII/FEDER “Una manera de hacer Europa” (PI18/00573 & PI21/00294 to R.M. Martí), CIBERONC-CB16/12/00231, and Generalitat de Catalunya (2021/SGR0093). The research at the Melanoma group in Hospital Clinic Barcelona is supported by the CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain; AGAUR 2017_SGR_1134 and

CERCA Programme by Generalitat de Catalunya, Spain; a Research Grant from “Fundación Científica de la Asociación Española Contra el Cáncer” GCB15152978SOEN, Spain; European Commission under the sixth Framework Programme, Contract No. LSHC-CT-2006-018702 (GenoMEL), by the European Commission under the seventh Framework Programme, Diagnostopics; the European Commission under the HORIZON2020 Framework Programme, iTobos and Qualitop; and European Commission under the Horizon Europe Programme, HORIZON-MISS-2021-CANCER-02, MELCAYA (reference 101096667). This research was in part supported by grants from Fondo de Investigaciones Sanitarias P.I. 18/00419 and 22/01467 Spain. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. J. Angel-Baldo held a predoctoral fellowship from IRBLleida/Diputació de Lleida.

Conflict of interests

The authors state that they have no conflict of interests.

Acknowledgements

Thanks to our patients and their families who are the main reason for our studies. Special thanks to all fellows and

residents who contributed to keep updated our Network Database in daily clinical practice.

Appendix 1. Collaborators of the Network of Melanoma Centers of Catalonia

Clara Matas-Nadal, Xavier Soria, Sonia Gatiús, Felip Vilardell (Hospital Universitari Arnau de Vilanova, Lleida), Inma Gil, Cristina Grau, Fani Martínez (Hospital Universitari Sant Joan de Reus), Nelson Lobos (Hospital Clínic de Barcelona, Barcelona), Oriol Yélamos, Joan Dalmau (Hospital de la Santa Creu i Sant Pau, Barcelona), Carlos González-Cruz, Helena Hilari (Hospital Universitari Vall d'Hebrón), Paola Pasquali (Pius Hospital de Valls), Marc Sagristà (Hospital de Calella), María Rosa Olivella-Garcés (Hospital Moisès Broggi, Consorci Sanitari Integral, Sant Joan Despí), Montserrat Bonfill-Ortí, Josep Ramón Ferreres (Hospital Universitari de Bellvitge), Ane Jaka, Ariadna Quer, Nina Richarz (Hospital Universitari Germans Trias i Pujol, Badalona), Inés Zarzoso Muñoz, Emili Masferrer (Hospital Universitari Mútua Terrassa), Pedro Zaballos (Hospital Sant Pau i Santa Tecla, Tarragona), Manel Formigon (Consorci Sanitari de Terrassa), Loida Galvany (Hospital Dos de Maig), Marta Alegre (Hospital Plató, Barcelona), Anna Sánchez-Puigdollers, Nerea Mohino-Farré (Hospital Joan XXIII, Tarragona).

References

- Carrera C, Puig-Butille JA. Clinical, epidemiological, and molecular heterogeneity in acral melanoma. *J Invest Dermatol*. 2018;138:254–5, <http://dx.doi.org/10.1016/j.jid.2017.09.027>.
- Carrera C, Gual A, Diaz A, Puig-Butillé JA, Nogués S, Vilalta A, et al. Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians. *Melanoma Res*. 2017;27:315–20, <http://dx.doi.org/10.1097/CMR.0000000000000340>.
- Haugh AM, Zhang B, Quan VL, Garfield EM, Bubley JA, Kudalkar E, et al. Distinct patterns of acral melanoma based on site and relative sun exposure. *J Invest Dermatol*. 2018;138:384–93, <http://dx.doi.org/10.1016/j.jid.2017.08.022>.
- Teramoto Y, Keim U, Gesierich A, Schuler G, Fiedler E, Tüting T, et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. *Br J Dermatol*. 2018;178:443–51, <http://dx.doi.org/10.1111/bjd.15803>.
- Cho KK, Cust AE, Foo YM, Long GV, Menzies AM, Esllick GD. Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis. *Melanoma Res*. 2021;31:482–6, <http://dx.doi.org/10.1097/CMR.0000000000000764>.
- Kolla AM, Vitiello GA, Friedman EB, Sun J, Potdar A, Daou H, et al. Acral lentiginous melanoma: a United States multi-center substage survival analysis. *Cancer Control*. 2021;28, <http://dx.doi.org/10.1177/10732748211053567>.
- Bian SX, Hwang L, Hwang J, Ragab O, In GK, Peng D, et al. Acral lentiginous melanoma-population, treatment, and survival using the NCDB from 2004 to 2015. *Pigment Cell Melanoma Res*. 2021;34:1049–61, <http://dx.doi.org/10.1111/pcmr.12999>.
- Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. *Arch Pathol Lab Med*. 2020;144:500–22, <http://dx.doi.org/10.5858/arpa.2019-0561-RA>.
- Bernardes SS, Ferreira I, Elder DE, Nobre AB, Martínez-Said H, Adams DJ, et al. More than just acral melanoma: the controversies of defining the disease. *J Pathol Clin Res*. 2021, <http://dx.doi.org/10.1002/cjp2.233>. Published online July 2.
- Rex J, Paradelo C, Mangas C, Hilari JM, Fernández-Figueras MT, Ferrándiz C. Management of primary cutaneous melanoma of the hands and feet: a clinicoprognostic study. *Dermatol Surg*. 2009;35:1505–13, <http://dx.doi.org/10.1111/j.1524-4725.2009.01265.x>.
- Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986–2005. *Arch Dermatol*. 2009;145:427–34, <http://dx.doi.org/10.1001/archdermatol.2008.609>.
- Boriani F, O'Leary F, Tohill M, Orlando A. Acral Lentiginous Melanoma – misdiagnosis, referral delay and 5 years specific survival according to site. *Eur Rev Med Pharmacol Sci*. 2014;18:1990–6.
- Puig S, Marcoval J, Paradelo C, Azon A, Bartralt R, Bel S, et al. Melanoma incidence increases in the elderly of Catalonia but not in the younger population: effect of prevention or consequence of immigration? *Acta Derm Venereol*. 2015;95:422–6, <http://dx.doi.org/10.2340/00015555-1997>.
- Podlipnik S, Carrera C, Boada A, Richarz N, Marcoval J, Ferreres JR, et al. Incidence of melanoma in Catalonia, Spain, is rapidly increasing in the elderly population. A multicentric cohort study. *J Clin Med*. 2020;9:3396, <http://dx.doi.org/10.3390/jcm9113396>.
- Segura S, Podlipnik S, Boada A, Martí RM, Sabat M, Yélamos O, et al. Melanoma-specific survival is worse in the elderly: a multicentric cohort study. *Melanoma Res*. 2023;33:532–8, <http://dx.doi.org/10.1097/CMR.0000000000000923>.
- Hudson DA, Krige JE. Melanoma in black South Africans. *J Am Coll Surg*. 1995;180:65–71.
- Chi Z, Li S, Sheng X, Si L, Cui C, Han M, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. *BMC Cancer*. 2011;11:85, <http://dx.doi.org/10.1186/1471-2407-11-85>.
- Lee HY, Chay WY, Tang MB, Chio MT, Tan SH. Melanoma: differences between Asian and Caucasian patients. *Ann Acad Med Singap*. 2012;41:17–20.
- Quintella Mendes GL, Koifman S. Socioeconomic status as a predictor of melanoma survival in a series of 1083 cases from Brazil: just a marker of health services accessibility? *Melanoma Res*. 2013;23:199–205, <http://dx.doi.org/10.1097/CMR.0b013e32835e76f8>.
- Mejbel HA, Torres-Cabala CA, Milton DR, Ivan D, Feldmeyer L, Namikawa K, et al. Prognostic significance of acral lentiginous histologic type in T1 melanoma. *Mod Pathol*. 2021;34:572–83, <http://dx.doi.org/10.1038/s41379-020-0641-x>.
- Bello DM, Chou JF, Panageas KS, Brady MS, Coit DG, Carvajal RD, et al. Prognosis of acral melanoma: a series of 281 patients. *Ann Surg Oncol*. 2013;20:3618–25, <http://dx.doi.org/10.1245/s10434-013-3089-0>.
- Jung HJ, Kweon SS, Lee JB, Lee SC, Yun SJ. A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress. *JAMA Dermatol*. 2013;149:1281–8, <http://dx.doi.org/10.1001/jamadermatol.2013.5853>.
- Wada M, Ito T, Tsuji G, Nakahara T, Hagiwara A, Furue M, et al. Acral lentiginous melanoma versus other melanoma: a single-center analysis in Japan. *J Dermatol*. 2017;44:932–8, <http://dx.doi.org/10.1111/1346-8138.13834>.
- Paolino G, Bekkenk MW, Didona D, Eibenschutz L, Richetta AG, Cantisani C, et al. Is the prognosis and course of acral melanoma related to site-specific clinicopathological features? *Eur Rev Med Pharmacol Sci*. 2016;20:842–8.

25. Bosch-Amate X, Podlipnik S, Riquelme-Mc Loughlin C, Carrera C, Barreiro-Capurro A, García-Herrera A, et al. Clinicopathological, genetic and survival advantages of naevus-associated melanomas: a cohort study. *Acta Derm Venereol.* 2021;101:adv00425, <http://dx.doi.org/10.2340/00015555-3780>.
26. Dessinioti C, Geller AC, Stratigos AJ. A review of nevus-associated melanoma: what is the evidence? *J Eur Acad Dermatol Venereol.* 2022;36:1927–36, <http://dx.doi.org/10.1111/jdv.18453>.
27. Martín-Gorgojo A, Nagore E. Melanoma arising in a melanocytic nevus. *Actas Dermosifiliogr (Engl Ed).* 2018;109:123–32, <http://dx.doi.org/10.1016/j.ad.2017.06.009>.
28. Lee JH, Choi YD, Hwang JH, Shin MH, Yun SJ. Frequency of trauma, physical stress, and occupation in acral melanoma: analysis of 313 acral melanoma patients in Korea. *Ann Dermatol.* 2021;33:228–36, <http://dx.doi.org/10.5021/ad.2021.33.3.228>.
29. Zhang N, Wang L, Zhu GN, Sun DJ, He H, Luan Q, et al. The association between trauma and melanoma in the Chinese population: a retrospective study. *J Eur Acad Dermatol Venereol.* 2014;28:597–603, <http://dx.doi.org/10.1111/jdv.12141>.
30. Arango Abisaad J, Arciniegas Grisales V, Londoño García Á, Vasquez Trespalcacios EM, Jiménez Calfat G, Cuello López JM. Characteristics of acral lentiginous melanoma according to location in stress- or non-stress-bearing areas: a retrospective study of 95 patients. *Actas Dermosifiliogr.* 2022;113:134–40, <http://dx.doi.org/10.1016/j.ad.2021.08.006>.
31. Green A, McCredie M, MacKie R, Giles G, Young P, Morton C, et al. A case-control study of melanomas of the soles and palms (Australia and Scotland). *Cancer Causes Control.* 1999;10:21–5.
32. Tan KB, Moncrieff M, Thompson JF, McCarthy SW, Shaw HM, Quinn MJ, et al. Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting. *Am J Surg Pathol.* 2007;31:1902, <http://dx.doi.org/10.1097/PAS.0b013e318073c600>.
33. Mejbel HA, Torres-Cabala CA, Milton DR, Ivan D, Nagarajan P, Curry JL, et al. Prognostic significance of subungual anatomic site in acral lentiginous melanoma. *Arch Pathol Lab Med.* 2021;145:943–52, <http://dx.doi.org/10.5858/arpa.2020-0308-OA>.
34. Borges de Barros Primo R, Brito Nobre A, Santos BN, Nunes LF, Fernandes R, Abrão Possik P, et al. Impact of clinical and histopathological characteristics on the disease-free survival of stage I–II acral melanoma patients. *Int J Dermatol.* 2023;62:1281–8, <http://dx.doi.org/10.1111/ijd.16800>.
35. Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. *PLoS ONE.* 2012;7:e32955, <http://dx.doi.org/10.1371/journal.pone.0032955>.
36. Tejera-Vaquero A, Barrera-Vigo MV, Fernández-Canedo I, Blázquez-Sánchez N, Mendiola-Fernández M, Fernández-Orland A, et al. Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma. *Actas Dermosifiliogr.* 2007;98:531–8.
37. Marcoval J, Ferreres JR, Martín C, Gómez S, Penín RM, Ochoa de Olza M, et al. Patterns of visceral metastasis in cutaneous melanoma: a descriptive study. *Actas Dermosifiliogr.* 2013;104:593–7, <http://dx.doi.org/10.1016/j.adengl.2012.12.006>.
38. von Schuckmann LA, Hughes MCB, Ghiasvand R, Malt M, van der Pols JC, Beesley VL, et al. Risk of melanoma recurrence after diagnosis of a high-risk primary tumor. *JAMA Dermatol.* 2019;155:688–93, <http://dx.doi.org/10.1001/jamadermatol.2019.0440>.
39. Hohnheiser AM, Gefeller O, Göhl J, Schuler G, Hohenberger W, Merkel S. Malignant melanoma of the skin: long-term follow-up and time to first recurrence. *World J Surg.* 2011;35:580–9, <http://dx.doi.org/10.1007/s00268-010-0859-8>.
40. Meier F, Will S, Ellwanger U, Schlagenhauß B, Schitteck B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. *Br J Dermatol.* 2002;147:62–70, <http://dx.doi.org/10.1046/j.1365-2133.2002.04867.x>.
41. Leiter U, Meier F, Schitteck B, Garbe C. The natural course of cutaneous melanoma. *J Surg Oncol.* 2004;86:172–8, <http://dx.doi.org/10.1002/jso.20079>.
42. Ertekin SS, Podlipnik S, Riquelme-Mc Loughlin C, Barreiro-Capurro A, Arance A, Carrera C, et al. Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence. *Acta Derm Venereol.* 2021;101, <http://dx.doi.org/10.2340/00015555-3832>, adv00502.
43. Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillet B, et al. Association of time from primary diagnosis to first distant relapse of metastatic melanoma with progression of disease and survival. *JAMA Dermatol.* 2019;155:673–8, <http://dx.doi.org/10.1001/jamadermatol.2019.0425>.
44. Calomarde-Rees L, García-Calatayud R, Requena Caballero C, Manrique-Silva E, Traves V, García-Casado Z, et al. Risk factors for lymphatic and hematogenous dissemination in patients with stages I–II cutaneous melanoma. *JAMA Dermatol.* 2019;155:679–87, <http://dx.doi.org/10.1001/jamadermatol.2019.0069>.
45. Berghe AS, Cobzac G, Dindelegan G, Şenilă SC, Baican CI, Solomon CM, et al. Risk factors for positive sentinel lymph node, lymphatic or hematogenous dissemination over time in patients with cutaneous melanoma. *Exp Ther Med.* 2021;22:730, <http://dx.doi.org/10.3892/etm.2021.10162>.
46. Tas F, Erturk K. Relapse patterns in patients with local and regional cutaneous melanoma. *Clin Transl Oncol.* 2019;21:412–9, <http://dx.doi.org/10.1007/s12094-018-1938-9>.
47. Baade PD, Whiteman DC, Janda M, Cust AE, Neale RE, Smithers BM, et al. Long-term deaths from melanoma according to tumor thickness at diagnosis. *Int J Cancer.* 2020;147:1391–6, <http://dx.doi.org/10.1002/ijc.32930>.
48. Tas F, Erturk K. Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors. *Melanoma Res.* 2017;27:134–9, <http://dx.doi.org/10.1097/CMR.0000000000000332>.
49. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. *J Clin Oncol.* 2010;28:3042–7, <http://dx.doi.org/10.1200/JCO.2009.26.2063>.
50. Lee AY, Droppelmann N, Panageas KS, Zhou Q, Ariyan CE, Brady MS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. *Ann Surg Oncol.* 2017;24:939–46, <http://dx.doi.org/10.1245/s10434-016-5642-0>.
51. Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous melanoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2019;17:367–402, <http://dx.doi.org/10.6004/jnccn.2019.0018>.